F-star Therapeutics

F-star Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing tetravalent bispecific antibodies to address the paradigm shift in cancer treatment. By developing drugs aimed at preventing tumor immune escape, the company's goal is to provide patients with greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent bispecific natural antibody (mAb²™) format, F-star's mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.